Munich-DE
Munich-DE-MOBILE

Transthyretin Amyloidosis (ATTR)

European Society of Cardiology (ESC) 2026

Congress Details

calander28-31 August, 2026 | Germany

locationMunich, Germany

The materials in this section are intended for UK healthcare professionals and include scientific and educational congress content related to vutrisiran▼ and patisiran. The information contained in these presentations and posters was accurate at the time of presentation. Healthcare professionals should consult the current full Prescribing Information [for the most up-to-date information on indications, dosing, contraindications, warnings, and adverse reactions].

Oral

Agenda

RNAiscience.co_.uk-ESC-2026-Amylo'ExTTRa-manifestations-in-FR-pts-with-ATTR-CM-POSTER
icon Presentation Type
Oral Presentation
location icon Location
Munich, Germany
icon Title
Amylo'ExTTRa: Exploring extra-cardiac manifestations in patients with ATTR-CM using a French National Health Data System
RNAiscience.co.uk - ESC 2026- Vutri & preservation of intrinsic capacity and healthy ageing POSTER
icon Presentation Type
Oral Presentation
location icon Location
Munich, Germany
icon Title
Vutrisiran is associated with preservation of intrinsic capacity and healthy ageing in patients with transthyretin amyloidosis with cardiomyopathy: Post hoc analysis of HELIOS-B
mic Presenter

Olivier Lairez

Toulouse University Hospital
Tolouse, France

RNAiscience.co.uk - ESC 2026- Fewer adverse events in ATTR-CM pts treated with AMV vs placebo POSTER
icon Presentation Type
Moderated Poster
location icon Location
Munich, Germany
icon Title
Fewer adverse events reported in ATTR-CM patients treated with vutrisiran versus placebo: post hoc safety analysis from HELIOS-B
mic Presenter

Stéphanie Schwarting

Ludwig Maximillian University of Munich
Munich, Germany

RNAiscience.co.uk - ESC 2026- Effect of Vutrisiran According to Baseline Tafamidis Use POSTER
icon Presentation Type
Oral presentation
location icon Location
Munich, Germany
icon Title
Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis with Cardiomyopathy: Insights from HELIOS-B
RNAiscience.co.uk - ESC 2026- Effect of Vutrisiran According to Baseline Tafamidis Use POSTER
icon Presentation Type
Oral presentation
location icon Location
Munich, Germany
icon Title
Cardiac presentation and treatment response by sex in patients with transthyretin amyloidosis: pooled analysis of vutrisiran and patisiran Phase 3 studies

Associated Materials

Transthyretin Amyloidosis (ATTR)

Diagnosis of hereditary transthyretin amyloidosis in patients with suspected chronic inflammatory demyelinating polyneuropathy unresponsive to intravenous immunoglobulins: results of a retrospective study

Orphanet Journal of Rare Diseases

Author(s)

Yann Péréon, David Adams, Jean-Philippe Camdessanché, et al

March 2025

Preparation Date
March 2026
Job Code
MB-UK-00172

Transthyretin Amyloidosis (ATTR)

Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis with Cardiomyopathy

Journal of the American College of Cardiology

Author(s)

Farooq H. Sheikh, Gilbert Habib, W. H. Wilson Tang, et al

March 2025

Preparation Date
March 2026
Job Code
MB-UK-00173

Transthyretin Amyloidosis (ATTR)

Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis with Cardiomyopathy

Journal of the American College of Cardiology

Author(s)

Mathew S. Maurer, Ronald M. Witteles, Pablo Garcia-Pavia, et al

March 2025

Preparation Date
March 2026
Job Code
MB-UK-00174
acc-usa-mobile

Transthyretin Amyloidosis (ATTR)

American College of Cardiology (ACC) 2025

29-31 March, 2025 USA

View Details
Preparation Date
March 2026
Job Code
MB-UK-00142

Transthyretin Amyloidosis (ATTR)

Worsening of Heart Failure in Outpatients With Transthyretin Amyloidosis and Cardiomyopathy in the APOLLO-B Trial

Journal of the American College of Cardiology

Author(s)

Marianna Fontana, Mathew S. Maurer, Julian D. Gillmore, et al

January 2025

Preparation Date
March 2026
Job Code
MB-UK-00176

Transthyretin Amyloidosis (ATTR)

Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy: A Randomized Clinical Trial With Open-Label Extension

JAMA Neurology

Author(s)

David Adams, Jonas Wixner, Michael Polydefkis, et al

January 2025

Preparation Date
March 2026
Job Code
MB-UK-00177
Preparation Date
August 2026
Job Code
MB-UK-00230